Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors
Phase 1 Completed
29 enrolled
Prevention of Recurrent Hepatitis B After Liver Transplantation
Completed
317 enrolled
Long-Term Study of Liver Disease in People With Hepatitis B and/or Hepatitis C With or Without HIV Infection
Completed
569 enrolled
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
Phase 1 Completed
58 enrolled 17 charts
Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver
Phase 1/2 Completed
25 enrolled 10 charts
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
Phase 1 Completed
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Phase 3 Completed
235 enrolled 12 charts
Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver
Phase 2 Completed
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
Phase 2 Completed
54 enrolled 14 charts
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase 3 Completed
356 enrolled 13 charts
A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area
Completed
1,871 enrolled
The Second Multicenter Hemophilia Cohort Study
Completed
2,565 enrolled
Long-term Follow-up of HALT-C Sustained Virological Responders
Completed
140 enrolled
Tremelimumab With Chemoembolization or Ablation for Liver Cancer
Phase 1/2 Completed
61 enrolled 18 charts
Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial
Phase 3 Completed
15 enrolled 18 charts
Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization
Phase 2 Completed
3 enrolled 5 charts
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
Phase 2 Completed
252 enrolled 20 charts
Sorafenib and TRC105 in Hepatocellular Cancer
Phase 1/2 Completed
27 enrolled 32 charts
Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery
Phase 2 Completed
57 enrolled 9 charts
Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Phase 1/2 Completed
54 enrolled 8 charts
S1310
Phase 2 Completed
53 enrolled 13 charts
TRC105 for Liver Cancer That Has Not Responded to Sorafenib
Phase 2 Completed
11 enrolled 10 charts
Tabectedin to Treat Children and Adolescents With Cancer
Phase 1 Completed
12 enrolled
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
Phase 2 Completed
8 enrolled 8 charts
Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
Phase 1 Completed
21 enrolled
Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery
Phase 2 Completed
29 enrolled 11 charts
Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer
Phase 2 Completed
46 enrolled 9 charts
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
Phase 1 Completed
43 enrolled
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer
Phase 2 Completed
27 enrolled 8 charts
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
Phase 1 Completed
80 enrolled
Hepatic Arterial Infusion With Melphalan in Treating Patients With Unresectable Liver Cancer
Phase 1 Completed
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer
Phase 2 Completed
26 enrolled 11 charts
Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
Phase 2 Completed
75 enrolled
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer
Phase 2 Completed
42 enrolled 8 charts
Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase 2 Completed
19 enrolled 8 charts
IMC-A12 in Treating Patients With Advanced Liver Cancer
Phase 2 Completed
24 enrolled 8 charts
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
Phase 1 Completed
41 enrolled
Megestrol in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Phase 3 Completed
300 enrolled
T900607 in Treating Patients With Unresectable Liver Cancer
Phase 2 Completed
Epirubicin and Thalidomide in Treating Patients With Liver Cancer
Phase 2 Completed
12 enrolled
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
Phase 2 Completed
30 enrolled
Tamoxifen in Treating Patients With Primary Liver Cancer
Phase 3 Completed
300 enrolled
Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer
Phase 3 Completed
Irinotecan and Flavopiridol in Treating Patients With Advanced Liver Cancer
Phase 2 Completed
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
Phase 2 Completed
Oxaliplatin in Treating Patients With Liver Cancer
Phase 2 Completed
32 enrolled
Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase 2 Completed
44 enrolled
Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer
Phase 2 Completed
78 enrolled
Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer)
Phase 2 Completed
55 enrolled
BCX-1777 in Treating Patients With Refractory Cancer
Phase 1 Completed